Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Beovu
|
| gptkbp:activities |
VEGF inhibitor
|
| gptkbp:appointed_by |
injection
|
| gptkbp:approves |
gptkb:2019
gptkb:FDA |
| gptkbp:brand |
gptkb:Beovu
|
| gptkbp:clinical_trial |
Phase III trials
|
| gptkbp:developed_by |
gptkb:Novartis
|
| https://www.w3.org/2000/01/rdf-schema#label |
brolucizumab
|
| gptkbp:ingredients |
C_22 H_28 N_6 O_5 S
|
| gptkbp:is_used_for |
treatment of neovascular age-related macular degeneration
|
| gptkbp:manager |
intravitreal
|
| gptkbp:side_effect |
retinal detachment
vision loss intraocular inflammation cataract formation |
| gptkbp:targets |
gptkb:vascular_endothelial_growth_factor_(VEGF)
|
| gptkbp:weight |
460.56 g/mol
|